Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ValiRx plc ( (GB:VAL) ) has issued an announcement.
ValiRx plc, through its subsidiary Inaphaea BioLabs, has entered into an agreement with Screenin3D Limited to utilize Inaphaea’s Patient Derived Cells (PDC) in Screenin3D’s UpScale3D lab-on-a-chip technology. This collaboration will initially focus on creating 3D tumor models for triple negative breast cancer, which will enhance commercial services for both companies. The agreement includes an upfront fee and an option for Screenin3D to acquire commercial rights, potentially boosting ValiRx’s capabilities and market access in oncology and women’s health.
More about ValiRx plc
ValiRx plc is a life science company specializing in early-stage cancer therapeutics and women’s health. The company focuses on accelerating the translation of innovative science into impactful medicines to improve patient lives. ValiRx works to streamline the drug development process from pre-clinical studies to investor-ready assets, connecting scientific, technical, and commercial domains.
YTD Price Performance: -3.23%
Average Trading Volume: 9,921,843
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.81M
For a thorough assessment of VAL stock, go to TipRanks’ Stock Analysis page.